Finder makes money from featured partners, but editorial opinions are our own.

How to buy Imugene (IMU) shares in Australia

Learn how to easily invest in Imugene shares.

Headquartered in New South Wales, Imugene is an Australian clinical-stage biotechnology company focused on researching, developing and commercialising cancer immunotherapies. Imugene is heavily involved in the gastrointestinal and breast cancer therapy sector, tackling both conditions with its cancer vaccine candidate HER-Vaxx. Imugene was founded in 2012 by Leslie Chong and Axel Hoos as Biolife Science, which was then listed on the ASX through a reverse merger with a shell corporation named Imugene, a previously failed drug development venture.

How to buy shares in Imugene

To buy shares listed in Australia such as Imugene , you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.

  1. Open and fund your brokerage account.
    Complete an application with your personal and financial details, including your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  2. Search for Imugene .
    Find the share by name or ticker symbol: IMU. Research its history to confirm it's a solid investment against your financial goals.
  3. Purchase now or later.
    Buy today with a market order or use a limit order to delay your purchase until Imugene reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
  4. Decide on how many to buy.
    At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  5. Check on your investment.
    Congratulations, you own a part of Imugene . Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.

Imugene stock price (ASX:IMU)

Use our graph to track the performance of IMU stocks over time.

Imugene shares at a glance

Information last updated 2024-04-17.
52-week range$0.039 - $0.15
50-day moving average $0.1086
200-day moving average $0.0888
Target price$0.34
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.01

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Name Product Standard brokerage fee Inactivity fee Asset class
eToro
Finder AwardExclusive
eToro
$0
US$10 per month if there’s been no log-in for 12 months
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
CFD service. Capital at risk.
Join the world's biggest social trading network when you trade stocks, commodities and currencies from the one account.
Moomoo Share Trading
$3
$0
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get an additional 30 days on top of the regular brokerage-free period for new accounts. T&Cs apply.
Trade shares on the ASX, the US markets and buy ETFs with Moomoo. Plus join a community over 20 million investors.
Tiger Brokers
Exclusive
Tiger Brokers
$5.50
$0
ASX shares, Global shares, US shares, ETFs
Finder exclusive: 10 no-brokerage US or ASX market trades in the first 180 days + 7% p.a. on uninvested cash with first deposit of any amount, plus US$30 TSLA + US$30 NVDA shares with deposits up to AU$2000. T&Cs apply.
Trade Australian, US and Asian stocks with no minimum deposit on Tiger Broker’s feature-packed platform.
CMC Invest
Finder Award
CMC Invest
$0
$0
ASX shares, Global shares, Options trading, US shares, ETFs
$0 brokerage on US, UK, Canadian and Japanese markets (FX spreads apply).
Trade over 45,000 shares and ETFs from Australia and 15 major global markets. Plus, buy Aussie shares or ETFs for $0 brokerage up to $1,000 (First buy order of each security, each day - excludes margin loan settled trades).
Webull
$4.90
$0
ASX shares, Global shares, Options trading, US shares, ETFs
Sign up & deposit $200 to get $100 of rewards value, or deposit $1,000 to get $200 worth. Up to $5,450 value available. T&Cs apply.
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.
Saxo Invested
Saxo Invested
$3
$0
ASX shares, Global shares, Options trading, US shares, ETFs
Access 22,000+ stocks on 50+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
loading

Is it a good time to buy Imugene stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Imugene price performance over time

Historical closes compared with the last close of A$0.083

1 week (2024-04-12) -9.78%
1 month (2024-03-19) -24.55%
3 months (2024-01-19) -20.95%
6 months (2023-10-19) 97.62%
1 year (2023-04-19) -40.71%
2 years (2022-04-19) -64.68%
3 years (2021-04-19) -57.44%
5 years (2019-04-18) 388.24%

Imugene financials

Revenue TTM $15 million
Gross profit TTM $11.8 million
Return on assets TTM -26.15%
Return on equity TTM -44.37%
Profit margin 0%
Book value 0.027
Market capitalisation $613.7 million

TTM: trailing 12 months

Imugene share dividends

We're not expecting Imugene to pay a dividend over the next 12 months.

Have Imugene 's shares ever split?

Imugene 's shares were split on a 1:7.5 basis on 11 November 2002. So if you had owned 7.5 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Imugene shares – just the quantity. However, indirectly, the new 650% higher share price could have impacted the market appetite for Imugene shares which in turn could have impacted Imugene 's share price.

Imugene share price volatility

Over the last 12 months, Imugene 's shares have ranged in value from as little as $0.039 up to $0.15. A popular way to gauge a stock's volatility is its "beta".

Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Imugene 's is 3.208. This would suggest that Imugene 's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Imugene overview

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask a Question

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our 1. Terms Of Service and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site